IL-6 can lead to upregulation of PD-1 and immune exhaustion (104), while promoting interleukin 17 (IL-17) production – which can be a disadvantage in patients with cancer to subduing T-cell activity and augmenting tumor cell proliferation (105–107). The gene discussed is IL17A; the disease is cancer.